Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $40 to $49.
May 15, 2024 | 11:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Insmed and raises the price target from $40 to $49.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs are likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100